| abstract |
FIELD: chemistry.SUBSTANCE: invention relates to E-2-aryl-2-trifluoromethyl-1-nitro-cyclopropane of general formula I, where X=C, R=R=H; X=C, R=Cl, R=H; X=C, R=R=Cl; X=C, R=Br, R=H; X=C, R=R=Br; X=C, R=C-C-alkyl, R=H; X=C, R=NO, R=H; X=C, R=COAlk, R=H; X=C, R=CF, R=H; X=C, R=OMe, R=H; X=C, R=R=OMe; X=C, R=F, R=H; X=C, R-R=-OCHO-; X=N, R=R=H. Also disclosed is a method of producing compounds I, consisting in batch addition of 4-15-fold molar excess of bromonitromethane and inorganic (preferably potassium carbonate) or organic (preferably 1,1-dimethyl-1,4,5,6-tetrahydropyrimidine) base to a solution of the corresponding α-(trifluoromethyl)styrene in a polar solvent, preferably dimethylsulphoxide (in case of an inorganic base) and 1,1,3,3-tetramethyl urea or N,N-dimethylformamide (in the case of an organic base) at room temperature.EFFECT: obtaining novel compounds which can be used in medicine as anticancer agents for rectal cancer cells and human myelogenous leukemia.7 cl, 1 tbl, 14 ex |